Studies of Ocular Complications of AIDS (SOCA)--Ganciclovir-Cidofovir CMV Retinitis Trial (GCCRT)

This study has been completed.
Information provided by (Responsible Party):
Johns Hopkins Bloomberg School of Public Health Identifier:
First received: September 23, 1999
Last updated: June 2, 2015
Last verified: June 2015

To compare the newest CMV retinitis drug, cidofovir, with a regimen of the ganciclovir intraocular device plus oral ganciclovir with respect to efficacy in preventing vision loss.

To compare a treatment regimen that incorporates highly active local therapy (ganciclovir device) with a treatment regimen that does not.

Condition Intervention Phase
Cytomegalovirus Retinitis
HIV Infections
Device: Ganciclovir implant and oral ganciclovir
Drug: Cidofovir intravenous
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Studies of Ocular Complications of AIDS (SOCA)--Ganciclovir-Cidofovir CMV Retinitis Trial (GCCRT)

Resource links provided by NLM:

Further study details as provided by Johns Hopkins Bloomberg School of Public Health:

Enrollment: 61
Study Start Date: May 1997
Study Completion Date: June 2000
Primary Completion Date: June 2000 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Ganciclovir implant and oral ganciclovir
Ganciclovir device and oral dose of Ganciclovir 1 gm three times daily
Device: Ganciclovir implant and oral ganciclovir
oral ganciclovir, 1 gm three times daily
Other Name: Vitraset
Experimental: Cidofovir IV (Intravenous)
cidofovir intravenous (IV) start off with 5 mg/kg once weekly for two doses then followed by 5 mg/kg every other week
Drug: Cidofovir intravenous
intravenous, 5 mg/kg once weekly for two doses, followed by 5 mg/kg every other week
Other Name: Vistide

Detailed Description:

Cytomegalovirus (CMV) is among the most frequently encountered opportunistic infections in patients with AIDS. In the era of prophylaxis for pneumocystic pneumonia, CMV disease is estimated to affect 45 percent of patients with AIDS sometime between the diagnosis of AIDS and death. Retinitis has been estimated to account for up to 85 percent of CMV disease in these patients, making CMV retinitis the most common ocular infection encountered. CMV retinitis is a relatively late-stage manifestation, associated with cluster of differentiation 4 (CD4) + T-cell counts < 100 cells/µL and often < 50 cells/µL.

All currently available treatments for CMV suppress viral replication but do not eliminate the virus from the body. Discontinuation of therapy is associated with a prompt relapse of the retinitis. Despite the use of chronic suppressive therapy, relapse of the retinitis generally occurs, at least with systemically administered anti-CMV drugs.

The first two treatments approved for CMV retinitis were intravenous ganciclovir and intravenous foscarnet. Both are given by daily intravenous infusions and therefore require central venous catheters. The development of newer treatments has focused not only on efficacious treatments, but also on treatments that do not require central venous catheters. Available treatments now include oral ganciclovir, the ganciclovir intraocular device, and intravenous cidofovir.

In vitro data suggest that combination therapies are synergistic in inhibiting viral replication; these therapies include a foscarnet-ganciclovir combination and a cidofovir-ganciclovir combination. In the SOCA--CMV Retinitis Retreatment Trial, the combination of intravenous ganciclovir and foscarnet was more effective than either drug alone for the treatment of relapsed retinitis. Therefore, the combination of intermittent intravenous cidofovir and daily oral ganciclovir may be an attractive therapy for relapsed disease because it may provide synergy for controlling both ocular and visceral disease while not necessitating either a central venous catheter or an intraocular surgical procedure.

The Ganciclovir-Cidofovir CMV Retinitis Trial (GCCRT) is a randomized, multicenter clinical trial. Patients will be assigned to receive one of two regimens: (1) ganciclovir intraocular device plus oral ganciclovir or (2) intravenous cidofovir. The intraocular device will be surgically implanted at baseline and again every 6 to 8 months in eyes with CMV retinitis. Oral ganciclovir is taken at a dose of 1 gram three times daily. Cidofovir will be administered intravenously at 5 mg/kg once weekly for 2 consecutive weeks and once every 2 weeks thereafter. If disease progression occurs in patients receiving cidofovir, patients will be given reinduction therapy, and oral ganciclovir at a dose of 1 gram three times per day will be added to the treatment. If patients assigned to cidofovir are unable to tolerate that regimen, an alternative systemic regimen will be recommended.

Study outcome variables include a decrease of three or more lines from baseline in best corrected visual acuity and rate of visual field loss. The study will also assess other variables including mortality, blood CMV and HIV load, quality of life, and medical costs.

Treatment assignment will not be masked to either patients or clinicians; however, reading of fundus photographs to determine both change in retinal involvement and progression will be masked.


Ages Eligible for Study:   13 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion criteria:

  • Age 13 years or older
  • Diagnosis of AIDS according to current Centers for Disease Control and Prevention (CDC) definition
  • Diagnosis of active CMV retinitis by a SOCA-certified ophthalmologist (involvement of any zone or amount of retina is allowed)
  • Best corrected visual acuity of 20/100 or better in at least one eye
  • At least one lesion 750 cells/µL or greater
  • Platelet count 50,000 cells/µL or greater
  • Willingness and ability, with the assistance of a caregiver if necessary to comply with treatment and follow up procedures
  • Willingness of all men and women of childbearing potential to practice adequate birth control to prevent pregnancies during the study and for 3 months afterwards
  • Collection of all baseline data within 5 days prior to randomization
  • Signed consent statement

Exclusion criteria:

  • Media opacities that preclude visualization of the fundus of all otherwise eligible eyes
  • Treatment for CMV retinitis with the ganciclovir intraocular implant within 9 months of study entry
  • Medical problems or drug or alcohol abuse sufficient to hinder adherence to treatment or follow up procedures
  • Unwillingness to refrain from breast-feeding during the study and for 3 months afterwards
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00000143

United States, California
Department of Ophthalmology, University of California, Irvine
Irvine, California, United States, 92697-4375
Shiley Eye Center Center, 0946, University of California, San Diego
La Jolla, California, United States, 92093-0946
Jules Stein Eye Institute, University of California, Los Angeles
Los Angeles, California, United States, 90095-7003
LAC/USC Medical Center, 5P21 Rand Schrader Clinic
Los Angeles, California, United States, 90033
Beckman Vision Center, University of California, San Francisco
San Francisco, California, United States, 94143
United States, Florida
Bascom Palmer Eye Institute, University of Miami
Miami, Florida, United States, 33136
University of South Florida, MDC Box 21
Tampa, Florida, United States, 33612-4799
United States, Georgia
The Emory Clinic, Emory University
Atlanta, Georgia, United States, 30322
United States, Illinois
Department of Ophthalmology, Northwestern University
Chicago, Illinois, United States, 60611
United States, Indiana
Division of Infectious Diseases, Indiana University, Indianapolis
Indianapolis, Indiana, United States, 46202-2879
United States, Louisiana
LSU Eye Center, Louisiana State University Medical Center
New Orleans, Louisiana, United States, 70112
United States, Maryland
The Wilmer Ophthalmological Institute, The Johns Hopkins University School of Medicine
Baltimore, Maryland, United States, 21287-9217
United States, Massachusetts
Harvard/BCH AIDS Clinical Trials Unit, Massachusetts General Hospital
Boston, Massachusetts, United States, 02114
United States, New Jersey
UMDNJ-New Jersey Medical School
Newark, New Jersey, United States, 07103-2499
United States, New York
Department of Ophthalmology, New York University Medical Center
New York, New York, United States, 10016
Department of Ophthalmology, New York Hospital-Cornell Medical Center
New York, New York, United States, 10021
Department of Ophthalmology, Mount Sinai School of Medicine
New York, New York, United States, 10029-6574
United States, North Carolina
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, United States, 27599-7030
United States, Texas
Cullen Eye Institute, Baylor College of Medicine
Houston, Texas, United States, 77030
Sponsors and Collaborators
Johns Hopkins Bloomberg School of Public Health
Study Chair: Douglas Jabs, MD SOCA Chairman's Office
  More Information

Additional Information:
Responsible Party: Johns Hopkins Bloomberg School of Public Health Identifier: NCT00000143     History of Changes
Other Study ID Numbers: NEI-42
Study First Received: September 23, 1999
Last Updated: June 2, 2015
Health Authority: United States: Federal Government

Additional relevant MeSH terms:
Cytomegalovirus Retinitis
Cytomegalovirus Infections
DNA Virus Infections
Eye Diseases
Eye Infections
Eye Infections, Viral
Herpesviridae Infections
Retinal Diseases
Virus Diseases
Anti-Infective Agents
Antiviral Agents
Pharmacologic Actions
Therapeutic Uses processed this record on October 09, 2015